Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer | Publicación